Atropine use in children after nerve gas exposure.
Lynch
Mary
M
D000927:Anticonvulsants / Q000627:therapeutic use; D000931:Antidotes / Q000627:therapeutic use*; D001285:Atropine / Q000627:therapeutic use*; D002619:Chemical Warfare Agents / Q000506:poisoning; D002648:Child; D002801:Cholinesterase Reactivators / Q000627:therapeutic use; D004189:Disaster Planning / Q000379:methods / Q000592:standards; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009498:Neurotoxins / Q000506:poisoning*; D010372:Pediatrics / Q000379:methods* / Q000592:standards; D011041:Poisoning / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011220:Pralidoxime Compounds / Q000627:therapeutic use; D023481:Terrorism / Q000517:prevention & control; D014481:United States
D000927:Anticonvulsants; D000931:Antidotes; D002619:Chemical Warfare Agents; D002801:Cholinesterase Reactivators; D018727:Muscarinic Antagonists; D009498:Neurotoxins; D011220:Pralidoxime Compounds; D001285:Atropine; C028797:pralidoxime